VR Logo

Mainz Biomed B.V. (MYNZ) download report


Healthcare | Diagnostics Services

Mainz Biomed B.V. (MYNZ) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.

IPO Date: 05-Nov-2021

CEO & Director: Mr. Guido Baechler

Chief Financial Officer: Mr. William J. Caragol

Listing: NASDAQ: MYNZ

Country: Germany

Headquarters: Mainz,

Website: https://mainzbiomed.com

Key Facts

Market cap: $141.70 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-11.69 Mln

Cash: $8.73 Mln

Total Debt: $0.00 Mln

Insider's Holding: 24.69%

Liquidity: Low

52 Week range: $5.00 - 30.00

Shares outstanding: 13,960,500

Stock Performance

Time Period Mainz Biomed B.V. (MYNZ) S&P BSE Sensex* S&P Small-Cap 600*
YTD-7.03-8.64-19.22
1 month-18.55-3.03-9.34
3 months-32.92-8.15-14.58
1 Year--1.28-17.64
3 Years--10.555.91
5 Years--11.525.64
10 Years--11.8110.10
As on 29-Jun-2022 *As on 30-Jun-2022